Trial reportThe Journal of allergy and clinical immunology2012
Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents.
Trial report in The Journal of allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02148796 (Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness), which is not on this map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.
- Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).The European respiratory journal · 2023Pooled it
- Neural mechanisms of mindfulness-based stress reduction in asthma.Scientific reports · 2026Trial
- Cockroach immunotherapy modulates dominant T-cell responses independent of allergen extract content.The Journal of allergy and clinical immunology · 2025Trial
- Asthma and sleep disordered breathing in the pediatric adenotonsillectomy trial for snoring study.Sleep & breathing = Schlaf & Atmung · 2024Trial
- Comprehensive home environmental intervention did not reduce allergen concentrations or controller medication requirements among children in Baltimore.The Journal of asthma : official journal of the Association for the Care of Asthma · 2023Trial
- Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.Lancet (London, England) · 2022Trial
- Trial
- Development and initial validation of the Asthma Severity Scoring System (ASSESS).The Journal of allergy and clinical immunology · 2020Trial
- Validation of the maximum symptom day among children with asthma.The Journal of allergy and clinical immunology · 2019Trial
- The School Inner-City Asthma Intervention Study: Design, rationale, methods, and lessons learned.Contemporary clinical trials · 2017Trial
- Trial
- Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents.The Journal of allergy and clinical immunology · 2016Trial
- Individualized Household Allergen Intervention Lowers Allergen Level But Not Asthma Medication Use: A Randomized Controlled Trial.The journal of allergy and clinical immunology. In practiceTrial
- Allergic load and symptom severity in children with tic disorders: a cross-sectional study.European journal of pediatrics · 2026Article
- Classroom microbiome signatures of pest management associate with reduced asthma symptoms.The Journal of allergy and clinical immunology · 2026Article
- Mechanistic study of inspiratory training in childhood Asthma: Rationale and methods of a pediatric clinical trial.Contemporary clinical trials communications · 2026Article
- Article
- Randomized trial of ultraviolet irradiation units installed in homes of children and adolescents with asthma.The journal of allergy and clinical immunology. Global · 2025Article
- Severe Paediatric Asthma Collaborative in Europe: real-world data on children on biologics.ERJ open research · 2025Article
- Comparative analysis of ambient, in-home, and personal exposures reveals associations between breathing zone pollutant levels and asthma exacerbations in high-risk children.Respiratory research · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 14 institutions in 1 country.
Funding
Abstract
backgroundAsthma severity is reflected in many aspects of the disease, including impairment and future risks, particularly for exacerbations. According to the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, however, to assess more comprehensively the severity of asthma the level of current treatment needed to maintain a level of control should be included.
objectiveDevelopment and validation of a new instrument, the Composite Asthma Severity Index (CASI), which can quantify disease severity by taking into account impairment, risk, and the amount of medication needed to maintain control. At present, there is no instrument available to measure and assess the multidimensional nature of asthma.
methodsTwenty-six established asthma investigators, who are part of the National Institutes of Health-supported Inner City Asthma Consortium, participated in a modified Delphi consensus process to identify and weight the dimensions of asthma. Factor analysis was performed to identify independent domains of asthma by using the Asthma Control Evaluation trial. CASI was validated by using the Inner City Anti-IgE Therapy for Asthma trial.
resultsCASI scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measures, and exacerbations. At Asthma Control Evaluation trial enrollment, CASI ranged from 0 to 17, with a mean of 6.2. CASI was stable, with minimal change in variance after 1 year of treatment. In external validation, CASI detected a 32% larger improvement than did symptoms alone.
conclusionCASI retained its discriminatory ability even with low levels of symptoms reported after months of guidelines-directed care. Thus, CASI has the ability to determine the level of asthma severity and provide a composite clinical characterization of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.